Novel biologic therapies for psoriasis. - Wikidata - wikimedia - TriplyDB

Novel biologic therapies for psoriasis.

Novel biologic therapies for psoriasis.

http://www.wikidata.org/entity/Q35790897

about

Effector and suppressor roles for LFA-1 during the development of experimental autoimmune encephalomyelitis.A possible mechanism for hepatotoxicity induced by BIRB-796, an orally active p38 mitogen-activated protein kinase inhibitor.

P2860

Q41951909-10BB33BA-61BF-4526-8EBD-9756E2AC6FEB Q42750295-7E70BE28-5971-4980-B13A-B06AC8F6BCA5

P2860

Novel biologic therapies for psoriasis.

http://www.wikidata.org/entity/Q35790897

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Novel biologic therapies for psoriasis.

@ast

Novel biologic therapies for psoriasis.

@en

type

label

Novel biologic therapies for psoriasis.

@ast

Novel biologic therapies for psoriasis.

@en

prefLabel

Novel biologic therapies for psoriasis.

@ast

Novel biologic therapies for psoriasis.

@en

P1433

Q35790897-6467DEAB-E331-48ED-A27C-6B09C7AD0579

P1476

Q35790897-F1403100-C75D-4D3F-9FFD-92B74AD8CFC3

P2093

Q35790897-2F33FC0A-2BB8-4DEC-8D18-B57B4EBD66A1

Q35790897-E5B59862-0C1C-46E3-BCAF-C88CF030127C

P2860

Q35790897-01FDAD26-5488-4B4F-85EE-E89818B7F995

Q35790897-026064F7-9CCB-4A5B-9082-A4A984EA3619

Q35790897-0901B1EE-57B4-41E9-BA5A-40E7EA0B86DA

Q35790897-16E2CD18-558F-4818-94BB-E2BC8B958D92

Q35790897-17D3C730-3B9F-4982-B462-188543BE745A

Q35790897-21A3C555-C166-4F61-B346-882268C0FCB8

Q35790897-25910C27-FBF1-4F71-AEE9-98CB77F804A4

Q35790897-2993645D-F78D-4854-883A-E65EE1F34ECE

Q35790897-379BB122-E665-43A2-B21A-4CC093B6FD2A

Q35790897-41D89D58-A185-43B7-B6BA-05B635E3B109

P304

Q35790897-DF88B91D-55A1-4540-8D22-CD00EE0B2E6C

P31

Q35790897-D6C83D2B-1BF5-493F-8690-BE77DFA38A9B

P356

Q35790897-A1767E12-256E-47F3-9F26-9BF6C9969D6E

P407

Q35790897-32E9A330-FCCB-4D9F-A41A-C0E7BB42AAE9

P433

Q35790897-EC6B6DC5-D8B4-4941-843F-6C0BE940B479

P478

Q35790897-79436EAD-56F4-4CC2-A2D0-2164A58EED22

P577

Q35790897-C33D850E-568D-4CF5-B022-4275B439BF91

P698

Q35790897-3972360D-9FC7-4B8D-AFFC-BBC33E285382

P356

14712598.4.6.975

P1433

Expert Opinion on Biological Therapy

P1476

Novel biologic therapies for psoriasis.

@en

P2093

Brian Kirby

http://www.w3.org/2001/XMLSchema#string

Jane Barry

http://www.w3.org/2001/XMLSchema#string

P2860

Dendritic cells and the control of immunity

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.

Development of a recombinant growth factor and fusion protein: lessons from GM-CSF.

CD28/CTLA-4 and CD80/CD86 families: signaling and function.

Inflammatory skin diseases, T cells, and immune surveillance.

Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial.

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions.

P304

975-987

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.4.6.975

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15174979

http://www.w3.org/2001/XMLSchema#string